This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morecki, S. Articles by Slavin, S. Search for Related Content PubMed PubMed Citation Articles by Morecki, S. Articles by Slavin, S.

Allogeneic Cell Therapy for a Murine Mammary Carcinoma¹

Department of Bone Marrow Transplantation, Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem 91120, Israel

The effect of allogeneic cell therapy on tumor growth was studied in a murine model of mammary carcinoma (4T1) as an experimental model of solid tumors in humans. i.v. inoculation of 4T1 (H-2^d) cells into syngeneic mice [BALB/c or (BALB/cXC57BL/6)F₁] (F₁) carrying the H-2^d histocompatible antigens results in tumor colonies in the lungs that finally cause the death of all of the mice. Sublethally irradiated F₁ mice were inoculated with 4T1 cells to simulate minimal residual disease and with immunocompetent splenocytes derived from naive donors of F₁ (syngeneic), BALB/c (syngeneic to the tumor but semiallogeneic to the host), or C57BL/6 (allogeneic to the tumor and semiallogeneic to the host) mice. The survival of F₁ tumor-bearing mice that were treated with allogeneic C57BL/6 splenocytes was significantly prolonged (P < 0.02) compared with hosts given F₁ or BALB/c-derived splenocytes that are syngeneic to 4T1 tumor cells. Adoptive transfer of lung cells that were isolated from F₁ primary mice inoculated with 4T1 cells and syngeneic BALB/c or F₁ splenocytes led to local tumor growth and death in secondary recipients. In contrast, only 1 of 22 secondary recipients developed tumors when inoculated with lung cells derived from F₁ mice given allogeneic C57BL/6 splenocytes. All of the 21 secondary hosts survived disease-free for a follow-up time of >200 days. These results indicate that immunocompetent cells allogeneic to the mammary carcinoma cells were able to inhibit tumor development in the primary hosts and to prevent tumor growth in the adoptive recipients, which suggests that allogeneic cell therapy may be an efficient antitumor tool to eradicate minimal residual disease in human solid tumors.

¹ Supported in part by Baxter International Corporation, the German/Israel Foundation, and the Gabriella Rich Fund. The authors also thank Mr. & Mrs. S. Swartz and Mr. & Mrs. E. Reinstein.

² To whom requests for reprints should be addressed, at Department of Bone Marrow Transplantation, Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, POB 12000, Jerusalem 91120, Israel. Phone: 972-2-677-7270; Fax: 972-2-642-2731.

Received 4/ 6/98. Accepted 7/ 3/98.

This article has been cited by other articles:

				S. Morecki, H. Lindhofer, E. Yacovlev, Y. Gelfand, and S. Slavin Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes Blood, February 15, 2006; 107(4): 1564 - 1569. [Abstract] [Full Text] [PDF]

				Y. Lin, Y. Zeng, J. Di, and S. Zeng Murine CD200+CK7+ trophoblasts in a poly (I:C)-induced embryo resorption model Reproduction, October 1, 2005; 130(4): 529 - 537. [Abstract] [Full Text] [PDF]

				M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF]

				M. R. Bishop, D. H. Fowler, D. Marchigiani, K. Castro, C. Kasten-Sportes, S. M. Steinberg, J. C. Gea-Banacloche, R. Dean, C. K. Chow, C. Carter, et al. Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer J. Clin. Oncol., October 1, 2004; 22(19): 3886 - 3892. [Abstract] [Full Text] [PDF]

				Y. Takahashi and R. W. Childs Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6353S - 6359S. [Abstract] [Full Text] [PDF]

				U. Jung, J. E. Foley, A. A. Erdmann, M. A. Eckhaus, and D. H. Fowler CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects Blood, November 1, 2003; 102(9): 3439 - 3446. [Abstract] [Full Text] [PDF]

				M. Renga, P. Pedrazzoli, and S. Siena Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors Ann. Onc., August 1, 2003; 14(8): 1177 - 1184. [Abstract] [Full Text] [PDF]

				L. Luznik, J. E. Slansky, S. Jalla, I. Borrello, H. I. Levitsky, D. M. Pardoll, and E. J. Fuchs Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras Blood, February 15, 2003; 101(4): 1645 - 1652. [Abstract] [Full Text] [PDF]

				R. F. Storb, G. Lucarelli, P. A. McSweeney, and R. W. Childs Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors Hematology, January 1, 2003; 2003(1): 372 - 397. [Abstract] [Full Text] [PDF]

				L. D. Anderson Jr., D. Petropoulos, L. A. Everse, and C. A. Mullen Enhancement of Graft-Versus-Tumor Activity and Graft-Versus-Host Disease by Pretransplant Immunization of Allogeneic Bone Marrow Donors with a Recipient-derived Tumor Cell Vaccine Cancer Res., April 1, 1999; 59(7): 1525 - 1530. [Abstract] [Full Text] [PDF]